Skip to content

Innovative methodology: The development of a method to measure flow-based thrombin generation

Innovative methodology: The development of a method to measure flow-based thrombin generation - Diagnostic assay to measure secundairy hemostasis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON37888
Enrollment
120
Registered
2012-03-28
Start date
2012-04-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

clotting hemostasis

Interventions

None listed

Sponsors

Medisch Universitair Ziekenhuis Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Healthy men and women aged 18 to 65 years • Signed written consent to take part in the study

Exclusion criteria

Exclusion criteria: • Use of oral anticoagulants • Use of oral anti- platelet drugs • History of thrombosis and/or bleeding

Design outcomes

Primary

MeasureTime frame
The following parameters will be measured in the blood samples: • Thrombus generation and coagulation under flow in vitro. Thrombin generation is a dynamical process which includes platelets, coagulation factors and other blood cells. Thrombin generation can be triggered with different concentrations of tissue factor. • Control experiments need to be carried out per blood sample to check platelet count, quality, plasma quality and quality of whole blood using the standard procedures of our laboratory (flow cytometry, aggregometry, clotting). The main study parameters are thrombin generation and coagulation under flow conditions in vitro. Four different shear rates will be used to mimic arterial and venous blood flow and results will be compared. Furthermore four different tissue factor concentrations will be used. When no effect of shear rate is found on thrombin generation the study will be cancelled.

Secondary

MeasureTime frame
NA.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)